Walter MassonMartín LoboLeandro BarbagelataAugusto Lavalle-CoboJuan P. Nogueira2026-08-252026-08-252024-01-07http://repositorio.uia.ac.cr/handle/123456789/5137Semaglutide is widely used for type 2 diabetes and weight management, although concerns remain regarding its pancreatic safety. This updated meta-analysis evaluated the risk of acute pancreatitis associated with different semaglutide regimens. Randomized placebo-controlled trials were systematically reviewed following PRISMA guidelines, and global and stratified analyses were performed. Twenty-one trials involving 34,721 patients were included. Semaglutide was not associated with an increased risk of acute pancreatitis compared with placebo. Similar findings were observed for oral, low-dose subcutaneous, and high-dose subcutaneous regimens. These results support the pancreatic safety of semaglutide across different therapeutic regimens, although further real-world evidence remains warranted.enArticle